Neuropathic Pain Drug Market Research Report by Type (Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia), by Treatment (Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type), by Indication, by Diagnosis, by Distribution, by End User - United States Forecast to 2025 - Cumulative Impact of COVID-19

The United States Neuropathic Pain Drug Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Neuropathic Pain Drug Market.

Market Segmentation & Coverage:

This research report categorizes the Neuropathic Pain Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Neuropathic Pain Drug Market studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

Based on Treatment, the Neuropathic Pain Drug Market studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type further studied across Ibuprofen and Naproxen.

Based on Indication, the Neuropathic Pain Drug Market studied across Diabetic Neuropathy and Spinal Stenosis.

Based on Diagnosis, the Neuropathic Pain Drug Market studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination further studied across CT, Electromyography, and MRI.

Based on Distribution, the Neuropathic Pain Drug Market studied across Online Pharmacies and Retail Pharmacies & Drug Stores.

Based on End User, the Neuropathic Pain Drug Market studied across Clinics and Hospitals.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the United States Neuropathic Pain Drug Market including Bristol-Myers Squibb and Company, Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., and Pfizer Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Neuropathic Pain Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the United States Neuropathic Pain Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Neuropathic Pain Drug Market?

4. What is the competitive strategic window for opportunities in the United States Neuropathic Pain Drug Market?

5. What are the technology trends and regulatory frameworks in the United States Neuropathic Pain Drug Market?

6. What are the modes and strategic moves considered suitable for entering the United States Neuropathic Pain Drug Market?

1.1. Objectives of the Study

1.2. Market Segmentation & Coverage

1.3. Years Considered for the Study

1.4. Currency & Pricing

1.5. Language

1.6. Stakeholders

2.1. Research Process

2.1.1. Define: Research Objective

2.1.2. Determine: Research Design

2.1.3. Prepare: Research Instrument

2.1.4. Collect: Data Source

2.1.5. Analyze: Data Interpretation

2.1.6. Formulate: Data Verification

2.1.7. Publish: Research Report

2.1.8. Repeat: Report Update

2.2. Research Execution

2.2.1. Initiation: Research Process

2.2.2. Planning: Develop Research Plan

2.2.3. Execution: Conduct Research

2.2.4. Verification: Finding & Analysis

2.2.5. Publication: Research Report

2.3. Research Outcome

3.1. Market Outlook

3.2. Type Outlook

3.3. Treatment Outlook

3.4. Indication Outlook

3.5. Diagnosis Outlook

3.6. Distribution Outlook

3.7. End User Outlook

3.8. Competitor Outlook

4.1. Introduction

5.1. Introduction

5.2. Drivers

5.3. Restraints

5.4. Opportunities

5.5. Challenges

6.1. Introduction

6.2. Phantom Limb Pain

6.3. Post Herpetic Neuralgia

6.4. Post-traumatic Neuropathy

6.5. Trigeminal Neuralgia

7.1. Introduction

7.2. Antidepressant Drugs Type

7.2.1. Serotonin Noradrenaline

7.2.2. Tricyclic Antidepressants

7.3. Medication Type

7.4. Multimodal Therapy

7.5. NSAIDs Type

7.5.1. Ibuprofen

7.5.2. Naproxen

8.1. Introduction

8.2. Diabetic Neuropathy

8.3. Spinal Stenosis

9.1. Introduction

9.2. Blood Tests

9.3. Imaging Physical Examination

9.3.1. CT

9.3.2. Electromyography

9.3.3. MRI

10.1. Introduction

10.2. Online Pharmacies

10.3. Retail Pharmacies & Drug Stores

11.1. Introduction

11.2. Clinics

11.3. Hospitals

12.1. Introduction

12.2. 360iResearch Competitive Strategic Window, by Type

12.3. 360iResearch Competitive Strategic Window, by Treatment

12.4. 360iResearch Competitive Strategic Window, by Indication

12.5. 360iResearch Competitive Strategic Window, by Diagnosis

12.6. 360iResearch Competitive Strategic Window, by Distribution

12.7. 360iResearch Competitive Strategic Window, by End User

13.1. 360iResearch FPNV Positioning Matrix

13.1.1. Quadrants

13.1.2. Business Strategy

13.1.3. Product Satisfaction

13.2. 360iResearch Market Ranking Analysis

13.3. 360iResearch Market Share Analysis

13.4. 360iResearch Competitive Scenario

13.4.1. Merger & Acquisition

13.4.2. Agreement, Collaboration, & Partnership

13.4.3. New Product Launch & Enhancement

13.4.4. Investment & Funding

13.4.5. Award, Recognition, & Expansion

14.1. Bristol-Myers Squibb and Company

14.2. Eli Lily and Company

14.3. GlaxoSmithKline PLC

14.4. Johnson & Johnson Services Inc.

14.5. Pfizer Inc.

15.1. Discussion Guide

15.2. Edition Details

15.3. License Details

15.4. Pricing Details

TABLE 1. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2025 (USD MILLION)

TABLE 2. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, 2017-2025 (USD MILLION)

TABLE 3. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, 2017-2025 (USD MILLION)

TABLE 4. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, 2017-2025 (USD MILLION)

TABLE 5. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, 2017-2025 (USD MILLION)

TABLE 6. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2017-2025 (USD MILLION)

TABLE 7. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, 2017-2025 (USD MILLION)

TABLE 8. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2025 (USD MILLION)

TABLE 9. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, 2017-2025 (USD MILLION)

TABLE 10. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, 2017-2025 (USD MILLION)

TABLE 11. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2017-2025 (USD MILLION)

TABLE 12. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, 2017-2025 (USD MILLION)

TABLE 13. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, 2017-2025 (USD MILLION)

TABLE 14. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, 2017-2025 (USD MILLION)

TABLE 15. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, 2017-2025 (USD MILLION)

TABLE 16. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, 2017-2025 (USD MILLION)

TABLE 17. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2017-2025 (USD MILLION)

TABLE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, 2017-2025 (USD MILLION)

TABLE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, 2017-2025 (USD MILLION)

TABLE 20. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, 2017-2025 (USD MILLION)

TABLE 21. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, 2017-2025 (USD MILLION)

TABLE 22. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, 2017-2025 (USD MILLION)

TABLE 23. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, 2017-2025 (USD MILLION)

TABLE 24. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, 2017-2025 (USD MILLION)

TABLE 25. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: SCORES

TABLE 26. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: BUSINESS STRATEGY

TABLE 27. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: PRODUCT SATISFACTION

TABLE 28. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: RANKING

TABLE 29. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: MERGER & ACQUISITION

TABLE 30. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 31. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 32. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: INVESTMENT & FUNDING

TABLE 33. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 34. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: EDITION DETAILS

TABLE 35. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: LICENSE DETAILS

TABLE 36. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: PRICING DETAILS